6. Standard meta‐analyses results.

	Serious adverse events	Total adverse events	Withdrawals due to adverse events	Serious Infection	TB reactivation	Lymphoma	Congestive heart failure
Abatacept	0.90 (0.64 to 1.28)	1.24 (0.97 to 1.60)	0.97 (0.57 to 1.63)	1.06 (0.52 to 2.16)	0.50 (0.03 to 8.11)	1.52 (0.06 to 37.53)	1.56 (0.06 to 38.44)
Adalimumab	0.95 (0.74 to 1.22)	0.99 (0.63 to 1.56)	1.21 (0.84 to 1.75)	1.03 (0.53 to 2.01)	2.14 (0.33 to 13.78)	0.95 (0.10 to 9.19)	Not estimable
Anakinra	1.04 (0.68 to 1.61)	1.69 (0.84 to 3.42)	0.65 (0.09 to 4.50)	3.24 (0.97 to 10.82)	Not estimable	0.08 (0.00 to 2.08)	Not estimable
Certolizumab	1.24 (0.85 to 1.80)	1.16 (0.86 to 1.56)	1.17 (0.69 to 1.97)	3.15 (1.24 to 7.98)	4.43 (0.50 to 39.09)	0.33 (0.01 to 8.09)	Not  estimable
Etanercept	1.12 (0.87 to 1.44)	1.14 (0.88 to 1.48)	0.98 (0.73 to 1.32)	1.12 (0.73 to 1.70)	1.48 (0.06 to 36.93)	2.40 (0.38 to 15.31)	0.84 (0.05 to 14.26)
Golimumab	1.04 (0.64 to 1.68)	1.30 (0.85 to 1.99)	1.26 (0.57 to 2.79)	1.24 (0.61 to 2.53)	3.04 (0.12 to 75.13)	Not estimable	2.84 (0.11 to 71.99)
Infliximab	1.06 (0.82 to 1.37)	1.51 (0.92 to 2.47)	1.99 (1.04 to 3.80)	1.34 (0.85 to 2.12)	2.82 (0.65 to 12.18)	3.00 (0.12 to 74.79)	Not estimable
Rituximab	1.59 (0.51 to 4.89)	1.69 (0.97 to 2.96)	1.93 (0.18 to 21.22)	0.39 (0.07 to 2.11)	‐‐‐	‐‐‐	‐‐‐
Tocilizumab	0.90 (0.51 to 1.61)	1.36 (0.95 to 1.96)	1.49 (0.74 to 3.01)	1.28 (0.34 to 4.82)	Not estimable	‐‐‐	Not estimable
	1.04 (0.94 to 1.16)	1.28 (1.11 to 1.48)	1.22 (1.02 to 1.47)	1.23 (0.99 to 1.52)	2.30 (0.95 to 5.55)	1.05 (0.36 to 3.06)	1.46 (0.25 to 8.63)